{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-041538","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.447612+00:00","generated_at":"2026-06-04T04:51:12.195540+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"TriSalus reports 77% Q4 revenue growth but warns of late 10-K filing due to stock-comp errors","bullets":["Q4 revenue $5.7M (+77% YoY); full year $18.5M (+49% YoY); gross margin improved to 90% and 86%.","Operating loss Q4 $14.1M, full year $54.2M (incl. $7.9M deSPAC costs); net loss $35.5M and $59.0M.","Basic/diluted EPS loss Q4 $1.56, full year $6.73 (vs. $75.01/$161.55 in 2022, impacted by deSPAC).","Will file late 10-K due to stock-based compensation errors; results are unaudited and subject to change.","CMS granted HCPCS code for TriNav; 510k clearance for TriNav Large and TriGuide; phase 1 trials enrollment completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-041538","json":"https://secwatch.observer/filing/0001104659-24-041538.json","markdown":"https://secwatch.observer/filing/0001104659-24-041538.md","text":"https://secwatch.observer/filing/0001104659-24-041538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924041538/0001104659-24-041538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924041538/tm2410283d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:51:12.195540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d1e8e288c81dc90626e6b80b130c9a52b5ab2cbf","claim":"TriSalus Life Sciences, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On April 1, 2024, TriSalus Life Sciences, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924041538/0001104659-24-041538-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}